CEM |
Cytotoxicity assay |
|
|
|
Cytotoxicity against CEM cells, CC50 = 5 μM. |
15615545 |
bone marrow cells |
Cytotoxicity assay |
|
15 days |
|
Cytotoxicity against human bone marrow cells assessed as inhibition of CFU-GM formation after 15 days, CC50 = 30 μM. |
17329103 |
RG2TK+ |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against HSV1-tk gene overexpressing RG2TK+ cells after 72 hrs by MTT assay, CC50 = 5.86 μM. |
18800764 |
HFF |
Function assay |
|
|
|
Inhibitory concentration of the drug against the cytopathic effect for AD169 strain of epstein barr virus-2 (HCMV) in human HFF cells, EC50 = 0.5 μM. |
8394933 |
Vero |
Function assay |
|
|
|
Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of HSV-2 AD Vero cells by 50%, EC50 = 0.23 μM. |
11585457 |
MRC-5 |
Function assay |
|
|
|
Inhibitory activity of compound against human cytomegalovirus (HCMV) in MRC-5 cells., EC50 = 9.4 μM. |
12723951 |
HEL |
Function assay |
|
|
|
Compound was tested for anti-viral activity against HSV-1(G) in HEL cells, EC50 = 0.06 μM. |
14643328 |
HFF |
Function assay |
|
|
|
Inhibition of HCMV Towne replication in HFF cells by plaque reduction assay, EC50 = 2.1 μM. |
15615545 |
HFF |
Function assay |
|
|
|
Inhibition of HCMV AD169 replication in HFF cells by CPE inhibition assay, EC50 = 2.2 μM. |
15615545 |
H-1 |
Function assay |
|
|
|
Inhibition of EBV replication in H1 cells by DNA hybridization assay, EC50 = 5 μM. |
15615545 |
H-1 |
Function assay |
|
|
|
Effective concentration required to inhibit Epstein-barr virus replication in H-1 cells in DNA hybridization assay, EC50 = 5 μM. |
15634003 |
Hel |
Function assay |
|
|
|
Effective concentration required to inhibit herpes simplex virus type 1 Kos strain induced cytopathicity in Hel cells, EC50 = 0.06 μM. |
15658858 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against HSV1 KOS in HEL cells, EC50 = 0.06 μM. |
16392791 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against HSV2 G in HEL cells, EC50 = 0.06 μM. |
16392791 |
HFF |
Function assay |
|
|
|
Inhibition of HCMV AD169 replication in HFF cells by cytopathic effect assay, EC50 = 0.15 μM. |
17004726 |
HFF |
Function assay |
|
|
|
Inhibition of HCMV towne replication in HFF cells by plaque reduction assay, EC50 = 1.8 μM. |
17004726 |
H1 |
Function assay |
|
|
|
Inhibition of EBV replication in H1 cells by DNA hybridization assay, EC50 = 5 μM. |
17004726 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against HSV1 KOS in HEL cells, EC50 = 0.019 μM. |
17181162 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against HSV2 in HEL cells, EC50 = 0.032 μM. |
17181162 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against HSV1 KOS in HEL cells, EC50 = 0.48 μM. |
17181162 |
CCL81 |
Antiviral assay |
|
|
|
Antiviral activity against HSV2 in CCL81 cells, EC50 = 1.5 μM. |
17188402 |
CCL81 |
Antiviral assay |
|
|
|
Antiviral activity against HSV1 in CCL81 cells, EC50 = 1.5 μM. |
17188402 |
Vero |
Antiviral assay |
|
36 to 48 hrs |
|
Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs, EC50 = 0.7 μM. |
17438061 |
Vero |
Antiviral assay |
|
36 to 48 hrs |
|
Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs, EC50 = 14.5 μM. |
17438061 |
Vero |
Antiviral assay |
|
36 to 48 hrs |
|
Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs, EC50 = 19.2 μM. |
17438061 |
Vero |
Antiviral assay |
|
36 to 48 hrs |
|
Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs, EC50 = 23.5 μM. |
17438061 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation, EC50 = 2.75 μM. |
17518459 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation, EC50 = 6.3 μM. |
17518459 |
HEL |
Antiviral assay |
|
7 days |
|
Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as reduction of plaque formation after 7days, EC50 = 1.3 μM. |
17539622 |
HEL |
Antiviral assay |
|
7 days |
|
Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as reduction of plaque formation after 7 days, EC50 = 4.8 μM. |
17539622 |
HEL |
Antiviral assay |
|
5 days |
|
Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days, EC50 = 2.3 μM. |
17622128 |
HEL |
Antiviral assay |
|
7 days |
|
Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 7 days, EC50 = 5.1 μM. |
17622128 |
HEL |
Antiviral assay |
|
7 days |
|
Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 7 days, EC50 = 8.7 μM. |
17622128 |
HEL |
Antiviral assay |
|
7 days |
|
Antiviral activity against CMV Davis in human HEL cells after 7 days, EC50 = 2.6 μM. |
17672445 |
HEL |
Antiviral assay |
|
7 days |
|
Antiviral activity against CMV AD169 in human HEL cells after 7 days, EC50 = 6.5 μM. |
17672445 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity against Cytomegalovirus CMV T2211 infected in HFF cells by SEAP reporter gene assay, EC50 = 1.1 μM. |
17709468 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity against Cytomegalovirus CMV T2417 with pol A809V mutant infected in HFF cells by SEAP reporter gene assay, EC50 = 2.6 μM. |
17709468 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity against Cytomegalovirus CMV T2542 with pol T813S mutant infected in HFF cells by SEAP reporter gene assay, EC50 = 2.7 μM. |
17709468 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity against Cytomegalovirus CMV T2420 with pol G841A mutant infected in HFF cells by SEAP reporter gene assay, EC50 = 3.5 μM. |
17709468 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity against Cytomegalovirus CMV T2258 with UL97 C592G mutant infected in HFF cells by SEAP reporter gene assay, EC50 = 3.9 μM. |
17709468 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity against Cytomegalovirus CMV T2784 with pol A809V UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay, EC50 = 6.1 μM. |
17709468 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity against Cytomegalovirus CMV T2798 with pol T813S UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay, EC50 = 6.6 μM. |
17709468 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity against Cytomegalovirus CMV 2817 with pol G841A UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay, EC50 = 8.4 μM. |
17709468 |
HEL |
Antiviral assay |
|
3 days |
|
Antiviral activity against HCMV Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days, EC50 = 1.3 μM. |
17961851 |
HEL |
Antiviral assay |
|
3 days |
|
Antiviral activity against HCMV AD169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days, EC50 = 4.8 μM. |
17961851 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity against Human cytomegalovirus Towne infected in HFF cells by plaque reduction assay, EC50 = 2.5 μM. |
18082410 |
hhTERT-BJ1 |
Antiviral assay |
|
2 days |
|
Antiviral activity against Human cytomegalovirus Towne infected in human hhTERT-BJ1 cells assessed as inhibition of virus mediated DNA synthesis after 2 days, EC50 = 3 μM. |
18458124 |
NIH 3T3 |
Antiviral assay |
|
4 to 5 days |
|
Antiviral activity against Murine cytomegalovirus strain Smith infected in mouse NIH 3T3 cells after 4 to 5 days by plaque reduction assay, EC50 = 5.7 μM. |
18458124 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against wild type HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 0.66 μM. |
19226140 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against acyclovir-resistant HCMV AD169 clone 1 infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 0.69 μM. |
19226140 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against wild type HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 0.7 μM. |
19226140 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against HPMPA-resistant HCMV AD169 clone 2 mutant infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 1.2 μM. |
19226140 |
HEL |
Antiviral assay |
|
7 days |
|
Antiviral activity against HCMV AD169 infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection, EC50 = 2 μM. |
19226140 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against foscarnet-resistant HCMV AD169 clone C infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 2.6 μM. |
19226140 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against PMEDAP-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 3.5 μM. |
19226140 |
HEL |
Antiviral assay |
|
7 days |
|
Antiviral activity against HCMV Davis infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection, EC50 = 3.6 μM. |
19226140 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against cidofovir HCMV AD169 clone 5 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 4 μM. |
19226140 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against ganciclovir-resistant HCMV AD169 clone 4 infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 4.3 μM. |
19226140 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity, EC50 = 0.02 μM. |
19281225 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against HSV2 G in human HEL cells assessed as protection against virus-induced cytopathicity, EC50 = 0.2 μM. |
19281225 |
feline FRCK |
Antiviral assay |
|
|
|
Antiviral activity against Feline herpesvirus in feline FRCK cells assessed as inhibition of virus-induced cytopathicity, EC50 = 1.2 μM. |
19281225 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity, EC50 = 9 μM. |
19281225 |
HEL |
Antiviral assay |
|
5 days |
|
Antiviral activity against Varicella zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days, EC50 = 0.59 μM. |
19339082 |
HEL |
Antiviral assay |
|
5 days |
|
Antiviral activity against Varicella zoster virus YS infected in human HEL cells assessed as inhibition of virus induced cytopathicity after 5 days, EC50 = 1.1 μM. |
19339082 |
HEL |
Antiviral assay |
|
5 days |
|
Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days, EC50 = 2.5 μM. |
19339082 |
HEL |
Antiviral assay |
|
7 days |
|
Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection, EC50 = 2.5 μM. |
19339082 |
HEL |
Antiviral assay |
|
7 days |
|
Antiviral activity against human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection, EC50 = 12.6 μM. |
19339082 |
foreskin fibroblast cells |
Antiviral assay |
|
|
|
Antiviral activity against Human cytomegalovirus AD169 infected in human foreskin fibroblast cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.04 μM. |
19397271 |
foreskin fibroblast cells |
Antiviral assay |
|
|
|
Antiviral activity against Human cytomegalovirus Towne infected in human foreskin fibroblast cells by plaque reduction assay, EC50 = 1.2 μM. |
19397271 |
embryonic fibroblast cells |
Antiviral assay |
|
|
|
Antiviral activity against Murine cytomegalovirus infected in mouse embryonic fibroblast cells by plaque reduction assay, EC50 = 5.5 μM. |
19397271 |
Vero |
Antiviral assay |
|
|
|
Antiviral activity against Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. |
19858259 |
Vero |
Antiviral assay |
|
|
|
Antiviral activity against Macacine herpesvirus 1 isolate MR3 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. |
19858259 |
Vero |
Antiviral assay |
|
|
|
Antiviral activity against Macacine herpesvirus 1 isolate MR4 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. |
19858259 |
Vero |
Antiviral assay |
|
|
|
Antiviral activity against Macacine herpesvirus 1 isolate MR5 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. |
19858259 |
Vero |
Antiviral assay |
|
|
|
Antiviral activity against Macacine herpesvirus 1 isolate MR6 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. |
19858259 |
Vero |
Antiviral assay |
|
|
|
Antiviral activity against Macacine herpesvirus 1 isolate MR7 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. |
19858259 |
Vero |
Antiviral assay |
|
|
|
Antiviral activity against Macacine herpesvirus 1 isolate MR8 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. |
19858259 |
Vero |
Antiviral assay |
|
|
|
Antiviral activity against Macacine herpesvirus 1 isolate MR9 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. |
19858259 |
Vero |
Antiviral assay |
|
|
|
Antiviral activity against Macacine herpesvirus 1 isolate MR10 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. |
19858259 |
Vero |
Antiviral assay |
|
|
|
Antiviral activity against Macacine herpesvirus 1 isolate MR11 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. |
19858259 |
Vero |
Antiviral assay |
|
|
|
Antiviral activity against Macacine herpesvirus 1 isolate MR1 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. |
19858259 |
Vero |
Antiviral assay |
|
|
|
Antiviral activity against Macacine herpesvirus 1 isolate MR2 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. |
19858259 |
Vero |
Antiviral assay |
|
|
|
Antiviral activity against Macacine herpesvirus 1 isolate A1 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. |
19858259 |
Vero |
Antiviral assay |
|
|
|
Antiviral activity against Macacine herpesvirus 1 isolate A2 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. |
19858259 |
Vero |
Antiviral assay |
|
|
|
Antiviral activity against Macacine herpesvirus 1 isolate A3 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. |
19858259 |
Vero |
Antiviral assay |
|
|
|
Antiviral activity against Macacine herpesvirus 1 isolate A4 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. |
19858259 |
Vero |
Antiviral assay |
|
|
|
Antiviral activity against Macacine herpesvirus 1 isolate A5 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. |
19858259 |
Vero |
Antiviral assay |
|
|
|
Antiviral activity against Macacine herpesvirus 1 isolate A6 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. |
19858259 |
Vero |
Antiviral assay |
|
|
|
Antiviral activity against Macacine herpesvirus 1 isolate MC1 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. |
19858259 |
Vero |
Antiviral assay |
|
|
|
Antiviral activity against Macacine herpesvirus 1 isolate MC2 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. |
19858259 |
Vero |
Antiviral assay |
|
|
|
Antiviral activity against Macacine herpesvirus 1 isolate MJ1 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. |
19858259 |
Vero |
Antiviral assay |
|
|
|
Antiviral activity against Macacine herpesvirus 1 isolate MJ2 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. |
19858259 |
Vero |
Antiviral assay |
|
|
|
Antiviral activity against Macacine herpesvirus 1 isolate MJ3 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. |
19858259 |
Vero |
Antiviral assay |
|
|
|
Antiviral activity against Macacine herpesvirus 1 isolate MP1 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. |
19858259 |
Vero |
Antiviral assay |
|
|
|
Antiviral activity against HSV1 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. |
19858259 |
Vero |
Antiviral assay |
|
|
|
Antiviral activity against HSV2 infected in african green monkey Vero cells by plaque reduction assay, EC50 = 19.3 μM. |
19858259 |
HEL |
Antiviral assay |
|
2 to 3 days |
|
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay, EC50 = 0.03 μM. |
20034711 |
HEL |
Antiviral assay |
|
2 to 3 days |
|
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay, EC50 = 0.03 μM. |
20034711 |
HEL |
Antiviral assay |
|
2 to 3 days |
|
Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay, EC50 = 0.03 μM. |
20034711 |
CRFK |
Antiviral assay |
|
|
|
Antiviral activity against Feline herpesvirus infected in cat CRFK cells assessed as protection from virus-induced cytopathogenicity by MTT assay, EC50 = 2.6 μM. |
20034711 |
HS27 |
Antiviral assay |
|
7 days |
|
Antiviral activity against human cytomegalovirus infected in human HS27 cells after 7 days by GFP-based fluorescent reduction assay, EC50 = 0.32 μM. |
20047911 |
MRC5 |
Antiviral assay |
|
7 days |
|
Antiviral activity against human cytomegalovirus infected in human MRC5 cells after 7 days by GFP-based fluorescent reduction assay, EC50 = 1.65 μM. |
20047911 |
HEL299 |
Antiviral assay |
|
7 days |
|
Antiviral activity against human cytomegalovirus infected in HEL299 cells after 7 days by GFP-based fluorescent reduction assay, EC50 = 2.39 μM. |
20047911 |
HEL |
Antiviral assay |
|
7 days |
|
Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days, EC50 = 0.05 μM. |
21128666 |
HEL |
Antiviral assay |
|
7 days |
|
Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days, EC50 = 0.08 μM. |
21128666 |
HEL |
Antiviral assay |
|
7 days |
|
Antiviral activity against acyclovir-resistant thymidine kinase deficient HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days, EC50 = 3 μM. |
21128666 |
HEL |
Antiviral assay |
|
7 days |
|
Antiviral activity against HCMV AD169/Davis infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days, EC50 = 5.2 μM. |
21128666 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.01 μM. |
21232828 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.04 μM. |
21232828 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.1 μM. |
21232828 |
HFF |
Antiviral assay |
|
1 hr |
|
Antiviral activity against Human cytomegalovirus (strain AD169) infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay, EC50 = 0.04 μM. |
21376429 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Human herpesvirus 2 G infected in HEL cells assessed as protection against virus-induced cytopathicity, EC50 = 0.027 μM. |
21565516 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity, EC50 = 0.03 μM. |
21565516 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as protection against virus-induced cytopathicity, EC50 = 6 μM. |
21565516 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as protection against virus-induced cytopathicity, EC50 = 6.54 μM. |
21565516 |
CRFK |
Antiviral assay |
|
|
|
Antiviral activity against Feline herpesvirus infected in CRFK cells assessed as protection against virus-induced cytopathicity, EC50 = 8.1 μM. |
21565516 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against acyclovir-resistant Human herpesvirus 1 KOS infected in HEL cells assessed as protection against virus-induced cytopathicity, EC50 = 15.7 μM. |
21565516 |
HEL |
Antiviral assay |
|
4 days |
|
Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis, EC50 = 0.03 μM. |
21696963 |
HEL |
Antiviral assay |
|
4 days |
|
Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis, EC50 = 0.03 μM. |
21696963 |
HEL |
Antiviral assay |
|
4 days |
|
Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis, EC50 = 0.8 μM. |
21696963 |
HEL |
Antiviral assay |
|
4 days |
|
Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days, EC50 = 0.02 μM. |
22459876 |
HEL |
Antiviral assay |
|
4 days |
|
Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days, EC50 = 0.03 μM. |
22459876 |
HEL |
Antiviral assay |
|
4 days |
|
Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as inhibition of virus plaque formation after 4 days, EC50 = 1.65 μM. |
22459876 |
HEL |
Antiviral assay |
|
4 days |
|
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation after 4 days, EC50 = 1.65 μM. |
22459876 |
CRFK |
Antiviral assay |
|
4 days |
|
Antiviral activity against Feline herpesvirus infected in cat CRFK cells assessed as inhibition of virus-induced cytopathic effect after 4 days by colorimetric formazan-based MTS assay, EC50 = 4.1 μM. |
22459876 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as reduction in virus-induced cytopathicity, EC50 = 7.1 μM. |
22578783 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus-induced cytopathicity, EC50 = 7.5 μM. |
22578783 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay, EC50 = 0.027 μM. |
22858222 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay, EC50 = 0.029 μM. |
22858222 |
CRFK |
Antiviral assay |
|
|
|
Antiviral activity against Feline herpesvirus infected in CRFK cells by viral CPE assay, EC50 = 1.15 μM. |
22858222 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against HCMV Davis infected in HEL cells by viral CPE assay, EC50 = 5.9 μM. |
22858222 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against HCMV AD169 infected in HEL cells by viral CPE assay, EC50 = 9.1 μM. |
22858222 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against thymidine kinase negative and ACV resistant HSV1 KOS infected in HEL cells by viral CPE assay, EC50 = 14.7 μM. |
22858222 |
CRFK |
Antiviral assay |
|
3 days |
|
Antiviral activity against Feline herpesvirus infected in CRFK cells assessed as inhibition of virus-induced cytopathicity after 3 days, EC50 = 1.2 μM. |
23047229 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.013 μM. |
23099097 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.015 μM. |
23099097 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against thymidine kinase deficient and acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 4 μM. |
23099097 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against HSV-1 KOS infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity, EC50 = 0.01 μM. |
23795238 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against HSV-2 G infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity, EC50 = 0.01 μM. |
23795238 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against ACV-resistant TK-deficient HSV-1 KOS infected in HEL cells assessed as inhibition of viral-induced cytopathogenicity, EC50 = 1 μM. |
23795238 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50 = 0.03 μM. |
23811093 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50 = 0.03 μM. |
23811093 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against TK-negative Herpes simplex virus 1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50 = 4 μM. |
23811093 |
CRFK |
Antiviral assay |
|
|
|
Antiviral activity against feline herpesvirus infected in cat CRFK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay, EC50 = 4.1 μM. |
23811093 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction of plaque formation, EC50 = 5.98 μM. |
23811093 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction of plaque formation, EC50 = 7.87 μM. |
23811093 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against human Cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity after, EC50 = 8.2 μM. |
23911854 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus plaque formation, EC50 = 0.38 μM. |
23911856 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity, EC50 = 0.9 μM. |
23911856 |
CRFK |
Antiviral assay |
|
|
|
Antiviral activity against Feline Herpes virus infected in cat CRFK cells assessed as inhibition of virus-induced cytopathic effect by MTS assay, EC50 = 0.9 μM. |
23911856 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Cytomegalovirus AD-169 infected in human HEL cells assessed as reduction in virus plaque formation, EC50 = 3.1 μM. |
23911856 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50 = 0.02 μM. |
26001344 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50 = 0.03 μM. |
26001344 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50 = 0.5 μM. |
26001344 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50 = 6.3 μM. |
26001344 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity, EC50 = 7.1 μM. |
26001344 |
HEL |
Antiviral assay |
|
7 days |
|
Antiviral activity against Human cytomegalovirus Davis expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy, EC50 = 4.72 μM. |
26291038 |
HEL |
Antiviral assay |
|
7 days |
|
Antiviral activity against Human cytomegalovirus AD169 expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy, EC50 = 6.12 μM. |
26291038 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against human cytomegalovirus Davis infected in HEL cells assessed as reduction in viral plaque formation, EC50 = 7.8 μM. |
26443550 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against human cytomegalovirus AD169 infected in HEL cells assessed as reduction in viral plaque formation, EC50 = 13.9 μM. |
26443550 |
Vero |
Antiviral assay |
|
3 days |
|
Antiviral activity against Herpes simplex virus 1 strain F VR-733 infected in African green monkey Vero cells after 3 days by MTT assay, EC50 = 0.9 μM. |
26460883 |
Vero |
Antiviral assay |
|
3 days |
|
Antiviral activity against Herpes simplex virus 2 strain MS VR-540 infected in African green monkey Vero cells after 3 days by MTT assay, EC50 = 1.4 μM. |
26460883 |
Vero |
Antiviral assay |
|
3 days |
|
Antiviral activity against Human cytomegalovirus Davis VR-807 infected in African green monkey Vero cells after 3 days by MTT assay, EC50 = 2.14 μM. |
26460883 |
Vero |
Antiviral assay |
|
3 days |
|
Antiviral activity against Varicella-zoster virus Ellen VR-1367 infected in African green monkey Vero cells after 3 days by MTT assay, EC50 = 11.1 μM. |
26460883 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Cytomegalovirus AD169 infected in HEL cells, EC50 = 0.25 μM. |
27128178 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Cytomegalovirus Davis 07/1 infected in HEL cells, EC50 = 0.4 μM. |
27128178 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus plaque formation, EC50 = 0.03 μM. |
27639368 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus plaque formation, EC50 = 0.09 μM. |
27639368 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation, EC50 = 2.1 μM. |
27639368 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus plaque formation, EC50 = 3.1 μM. |
27639368 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity, EC50 = 0.032 μM. |
27750154 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as reduction in virus-induced cytopathogenicity, EC50 = 0.055 μM. |
27750154 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against thymidine kinase-deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as reduction in virus-induced cytopathogenicity, EC50 = 4 μM. |
27750154 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Cytomegalovirus Davis infected in HEL cells assessed as reduction in virus plaque formation, EC50 = 6.5 μM. |
27750154 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Cytomegalovirus AD169 infected in HEL cells assessed as reduction in virus plaque formation, EC50 = 14.9 μM. |
27750154 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 8.7 μM. |
28682067 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against HCMV Davis strain infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 16.5 μM. |
28682067 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.03 μM. |
28757102 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against wild type Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.04 μM. |
28757102 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against thymidine kinase-deficient ACV-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.1 μM. |
28757102 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 2.96 μM. |
28757102 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 6.79 μM. |
28757102 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.03 μM. |
28829913 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Herpes simplex virus 2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 0.04 μM. |
28829913 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against ACV-resistant thymidine kinase deficient Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 4.3 μM. |
28829913 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 7.3 μM. |
28829913 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against human cytomegalovirus AD-169 infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50 = 7.4 μM. |
28829913 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as reduction in viral cytopathic effect, EC50 = 4.05 μM. |
29407990 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as reduction in viral cytopathic effect, EC50 = 5.63 μM. |
29407990 |
HEL |
Antiviral assay |
|
2 to 3 days |
|
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of plaque formation measured after 2 to 3 days post infection, EC50 = 0.019 μM. |
29550734 |
HEL |
Antiviral assay |
|
2 to 3 days |
|
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of plaque formation measured after 2 to 3 days post infection, EC50 = 0.045 μM. |
29550734 |
HEL |
Antiviral assay |
|
2 to 3 days |
|
Antiviral activity against thymidine kinase-deficient ACV-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of plaque formation measured after 2 to 3 days post infection, EC50 = 3.91 μM. |
29550734 |
HEL |
Antiviral assay |
|
6 to 7 days |
|
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of plaque formation measured after 6 to 7 days post infection, EC50 = 4.83 μM. |
29550734 |
HEL |
Antiviral assay |
|
6 to 7 days |
|
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of plaque formation measured after 6 to 7 days post infection, EC50 = 6.46 μM. |
29550734 |
HEL |
Antiviral assay |
|
2 to 3 days |
|
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection, EC50 = 0.051 μM. |
29670705 |
HEL |
Antiviral assay |
|
2 to 3 days |
|
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 2 to 3 days post-infection, EC50 = 0.057 μM. |
29670705 |
HEL |
Antiviral assay |
|
6 to 7 days |
|
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 6 to 7 days post-infection, EC50 = 3.31 μM. |
29670705 |
HEL |
Antiviral assay |
|
6 to 7 days |
|
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect measured after 6 to 7 days post-infection, EC50 = 7.41 μM. |
29670705 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 0.02 μM. |
29880251 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 0.02 μM. |
29880251 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against acyclovir-resistant thymidine kinase deficient Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 0.8 μM. |
29880251 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 2.29 μM. |
29880251 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against Human cytomegalovirus AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathicity, EC50 = 11.43 μM. |
29880251 |
HELF |
Antiviral assay |
|
|
|
Antiviral activity against Human herpesvirus 2 G strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity, EC50 = 0.03 μM. |
30098481 |
HELF |
Antiviral assay |
|
|
|
Antiviral activity against Human herpesvirus 1 KOS strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity, EC50 = 0.03 μM. |
30098481 |
HELF |
Antiviral assay |
|
|
|
Antiviral activity against thymidine kinase-deficient acyclovir-resistant Human herpesvirus 1 KOS strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity, EC50 = 0.5 μM. |
30098481 |
HELF |
Antiviral assay |
|
|
|
Antiviral activity against Human cytomegalovirus Davis strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity, EC50 = 6.52 μM. |
30098481 |
HELF |
Antiviral assay |
|
|
|
Antiviral activity against Human cytomegalovirus AD169 strain infected in HELF cells assessed as inhibition of virus-induced cytopathogenicity, EC50 = 11.75 μM. |
30098481 |
HEL |
Antiviral assay |
|
3 days |
|
Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method, EC50 = 0.01 μM. |
30286952 |
HEL |
Antiviral assay |
|
3 days |
|
Antiviral activity against Human herpesvirus 2 strain G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method, EC50 = 0.01 μM. |
30286952 |
HEL |
Antiviral assay |
|
3 days |
|
Antiviral activity against acyclovir-resistant TK-defecient Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method, EC50 = 0.2 μM. |
30286952 |
HFF |
Antiviral assay |
|
5 to 7 days |
|
Antiviral activity against HCMV infected HFF cells after 5 to 7 days by viral yield assay, EC99.9 = 5 μM. |
17329103 |
MRC-5 |
Antiviral assay |
|
|
|
In vitro antiherpesvirus activity against MRC-5 cells infected with HCMV (AD-169 strain), IC50 = 4 μM. |
1323678 |
BSC-1 |
Antiviral assay |
|
|
|
Antiviral activity of the compound was evaluated against the Herpes simplex virus type-1 in BSC-1 cells, IC50 = 3 μM. |
2913300 |
HEL |
Function assay |
|
|
|
Inhibition of human CMV DNA synthesis in CMV-infected HEL cells., IC50 = 0.5 μM. |
7752205 |
HEL |
Function assay |
|
|
|
Inhibition against DNA of uninfected HEL cells by incorporation of [3H]TdR., IC50 = 7 μM. |
7752205 |
BSC-1 |
Antiviral assay |
|
|
|
In vitro antiviral activity against HSV-1 virus in BSC-1 (monkey kidney) cells., IC50 = 3.5 μM. |
9057865 |
HFF |
Antiviral assay |
|
|
|
In vitro antiviral activity against HCMV (Towne strain) in HFF (human fibroblast) cells., IC50 = 7.4 μM. |
9057865 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity was determined by the HCMV plaque assay using HFF cells, IC50 = 7.7 μM. |
9057866 |
HFF |
Function assay |
|
|
|
Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by cytopathic effect inhibition assay, IC50 = 2.6 μM. |
9438017 |
MEF |
Function assay |
|
|
|
Inhibitory concentration against murine cytomegalovirus replication in MEF cells was determined by plaque reduction assay, IC50 = 3.4 μM. |
9438017 |
HFF |
Function assay |
|
|
|
Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by plaque reduction assay, IC50 = 7.4 μM. |
9438017 |
MRC-5 |
Function assay |
|
|
|
Inhibitory concentration for anti-HCMV activity against AD-169 strain in MRC-5 cells, IC50 = 6.3 μM. |
9836613 |
BSC-1 |
Antiviral assay |
|
|
|
Antiviral activity against HSV-1 (herpes simplex virus), determined by ELISA in quadruplicate wells using BSC-1 cells, IC50 = 3.5 μM. |
10882370 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity against towne strain HCMV was determined by plaque reduction assay in duplicate wells using HFF cells, IC50 = 7.4 μM. |
10882370 |
BSC-1 |
Function assay |
|
|
|
ELISA assay was performed using BSC-1 cells to determine activity against HSV-1, IC50 = 3.5 μM. |
10882372 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity against HCMV was determined by plaque reduction assay using HFF cells, IC50 = 7.4 μM. |
10882372 |
HFF |
Function assay |
|
|
|
Compound was tested for antiviral activity against C-4 Towne strain of HCMV in yield reduction assay using HFF cells, IC50 = 4.1 μM. |
10882374 |
HFF |
Function assay |
|
|
|
Compound was tested for antiviral activity against wild-type Towne strain of HCMV in yield reduction assay using HFF cells, IC50 = 4.5 μM. |
10882374 |
HFF |
Function assay |
|
|
|
Compound was tested for antiviral activity against Towne strain of HCMV in a plaque reduction assay using HFF cells, IC50 = 7.4 μM. |
10882374 |
HFF |
Function assay |
|
|
|
Compound was tested for antiviral activity against human cytomegalovirus (HCMV) by plaque reduction assay using HFF cells, IC50 = 7.4 μM. |
10882375 |
MRC-5 |
Function assay |
|
|
|
Concentration required to reduce viral plaque formation by Human Cytomegalovirus (HCMV) (strain AD-169) in MRC-5 cells, IC50 = 5.9 μM. |
10966740 |
MRC5 |
Function assay |
|
|
|
Inhibitory concentration against Davis strain of HCMV in MRC5 cells, IC50 = 1.4 μM. |
11454465 |
MRC5 |
Function assay |
|
|
|
Inhibitory concentration against Towne strain of HCMV in MRC5 cells, IC50 = 1.5 μM. |
11454465 |
MRC5 |
Function assay |
|
|
|
Inhibitory concentration against 2599R strain of HCMV in MRC5 cells, IC50 = 1.6 μM. |
11454465 |
MRC5 |
Function assay |
|
|
|
Inhibitory concentration against AD169 strain of HCMV in MRC5 cells, IC50 = 3 μM. |
11454465 |
BSC-1 |
Function assay |
|
|
|
Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay, IC50 = 3.5 μM. |
15509174 |
HFF |
Function assay |
|
|
|
Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay, IC50 = 7.4 μM. |
15509174 |
BSC-1 |
Function assay |
|
|
|
Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay, IC50 = 3.5 μM. |
15509175 |
HFF |
Function assay |
|
|
|
Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay, IC50 = 7.4 μM. |
15509175 |
HFF |
Function assay |
|
|
|
Inhibitory concentration required against human cytomegalovirus (HCMV) r56 strain (UL56 mutant gene) expressed in HFF cells was determined by plaque reduction assay, IC50 = 1.2 μM. |
15509176 |
HFF |
Function assay |
|
|
|
Inhibitory concentration required against human cytomegalovirus (HCMV) wild type expressed in HFF cells was determined by plaque reduction assay, IC50 = 1.2 μM. |
15509176 |
HFF |
Function assay |
|
|
|
Inhibitory concentration required against human cytomegalovirus (HCMV) D10 strain (UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay, IC50 = 1.2 μM. |
15509176 |
HFF |
Function assay |
|
|
|
Inhibitory concentration required against human cytomegalovirus (HCMV) C4 strain (UL56 + UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay, IC50 = 2.5 μM. |
15509176 |
BSC-1 |
Function assay |
|
|
|
Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay, IC50 = 3.5 μM. |
15509176 |
HFF |
Function assay |
|
|
|
Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay, IC50 = 7.4 μM. |
15509176 |
foreskin fibroblast cells |
Antiviral assay |
|
1 hr |
|
Antiviral activity against human cytomegalovirus Ad169 (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO, IC50 = 0.8 μM. |
16134946 |
foreskin fibroblast cells |
Antiviral assay |
|
1 hr |
|
Antiviral activity against human cytomegalovirus Ad169 (V823A) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO, IC50 = 0.8 μM. |
16134946 |
foreskin fibroblast cells |
Antiviral assay |
|
|
|
Antiviral activity against human cytomegalovirus (Davis strain) grown on human foreskin fibroblast cells determined by reduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO, IC50 = 1.3 μM. |
16134946 |
bone marrow cells |
Cytotoxicity assay |
|
|
|
Cytotoxicity against human bone marrow cells assessed as inhibition of colony forming unit of granulocyte/macrophage, IC50 = 30 μM. |
16814545 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity against Human CMV T2211 in HFF cells by SEAP assay, IC50 = 1.3 μM. |
17043128 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity against Human CMV T2241 in HFF cells by SEAP assay, IC50 = 1.4 μM. |
17043128 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity against Human CMV T2233 in HFF cells by SEAP assay, IC50 = 1.4 μM. |
17043128 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity against Human CMV AD169 in HFF cells by PRA, IC50 = 1.9 μM. |
17043128 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity against Human CMV T2291 in HFF cells by PRA, IC50 = 4.1 μM. |
17043128 |
MRC5 |
Antiviral assay |
|
|
|
Antiviral activity against Human CMV Towne in MRC5 cells by PRA, IC50 = 4.9 μM. |
17043128 |
MRC5 |
Antiviral assay |
|
|
|
Antiviral activity against Human CMV T2296 in MRC5 cells by PRA, IC50 = 5.4 μM. |
17043128 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity against Human CMV T2293 in HFF cells by SEAP assay, IC50 = 5.6 μM. |
17043128 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity against Human CMV T2291 in HFF cells by SEAP assay, IC50 = 7.1 μM. |
17043128 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity against Human CMV T2293 in HFF cells by PRA, IC50 = 10 μM. |
17043128 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity against Human CMV T2311 in HFF cells by PRA, IC50 = 12.4 μM. |
17043128 |
MRC5 |
Antiviral assay |
|
|
|
Antiviral activity against Human CMV T2287 in MRC5 cells by PRA, IC50 = 30.1 μM. |
17043128 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity against Human CMV T2311 in HFF cells by SEAP assay, IC50 = 30.2 μM. |
17043128 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity against HCMV Towne in HFF cells by plaque reduction assay, IC50 = 3 μM. |
17161946 |
OST TK-cells |
Cytotoxicity assay |
|
|
|
Cytotoxicity against human OST TK- cells expressing HSV1 TK, IC50 = 0.0019 μM. |
17181158 |
OST TK-cells |
Cytotoxicity assay |
|
|
|
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 2.5 uM 1-[6-(triphenylmethoxy)hexyl]thymine, IC50 = 0.018 μM. |
17181158 |
OST TK-cells |
Cytotoxicity assay |
|
|
|
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 5 uM 1-[6-(triphenylmethoxy)hexyl]thymine, IC50 = 0.033 μM. |
17181158 |
OST TK-cells |
Cytotoxicity assay |
|
|
|
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 10 uM 1-[6-(triphenylmethoxy)hexyl]thymine, IC50 = 0.041 μM. |
17181158 |
OST TK-cells |
Cytotoxicity assay |
|
|
|
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 2.5 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine, IC50 = 0.05 μM. |
17181158 |
OST TK-cells |
Cytotoxicity assay |
|
|
|
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 5 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine, IC50 = 0.081 μM. |
17181158 |
OST TK-cells |
Cytotoxicity assay |
|
|
|
Cytotoxicity against human OST TK- cells expressing HSV1 TK in presence of 10 uM 1-[6-[1,1-(diphenyl)-1-(4-pyridyl)methoxy]hexyl]thymine, IC50 = 0.11 μM. |
17181158 |
MRC5 |
Antiviral assay |
|
|
|
Antiviral activity against HCMV in MRC5 cells by plaque reduction assay, IC50 = 0.91 μM. |
17239594 |
HFF |
Antiviral assay |
|
5 days |
|
Antiviral activity against HCMV infected HFF cells after 5 days by dot blot assay, IC50 = 1 μM. |
17329103 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity against HCMV Davis in HFF cells by plaque reduction assay, IC50 = 1.3 μM. |
17434304 |
MCA-TK |
Cytotoxicity assay |
|
|
|
Cytotoxicity against MCA-TK cells, IC50 = 0.15 μM. |
17960926 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity against ganciclovir-sensitive HCMV1 isolate replication in HFF cells by plaque reduction assay, IC50 = 3.22 μM. |
19010684 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity against ganciclovir-resistant HCMV3 isolate replication in HFF cells by plaque reduction assay, IC50 = 16.4 μM. |
19010684 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity against Human cytomegalovirus infected in HFF cells by plaque reduction assay, IC50 = 1.3 μM. |
20167488 |
HFF |
Function assay |
|
|
|
Inhibition of HCMV DNA polymerase infected in HFF cells, IC50 = 1.3 μM. |
20403696 |
HFF |
Antiviral assay |
|
10 days |
|
Antiviral activity against Human cytomegalovirus Towne infected in HFF cells assessed as reduction in plaque formation after 10 days, IC50 = 3 μM. |
21641218 |
HFF |
Antiviral assay |
|
10 days |
|
Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay, IC50 = 0.14 μM. |
21812420 |
HFF |
Antiviral assay |
|
8 days |
|
Antiviral activity against HCMV infected in human HFF cells assessed as reduction in cytopathic effect after 8 days by plaque reduction assay, IC50 = 2.1 μM. |
22607883 |
HFF |
Function assay |
|
|
|
In vitro reduction in yield of Towne strain of HCMV in HFF (human fibroblast) cells., IC90 = 1.6 μM. |
9057865 |
HFF |
Function assay |
|
|
|
Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by yield reduction assay, IC90 = 1.6 μM. |
9438017 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity against towne strain HCMV was determined by yield reduction assay in duplicate wells using HFF cells, IC90 = 1.6 μM. |
10882370 |
HFF |
Antiviral assay |
|
|
|
Antiviral activity against HCMV was determined by yield reduction assay using HFF cells, IC90 = 1.6 μM. |
10882372 |
HFF |
Function assay |
|
|
|
Compound was tested for antiviral activity against Towne strain of HCMV in a yield reduction assay using HFF cells, IC90 = 1.6 μM. |
10882374 |
HFF |
Function assay |
|
|
|
Compound was tested for antiviral activity against wild-type AD169 strain of HCMV in yield reduction assay using HFF cells, IC90 = 3.3 μM. |
10882374 |
HFF |
Function assay |
|
|
|
Compound was tested for antiviral activity against 2916 AD169 strain of HCMV in yield reduction assay using HFF cells, IC90 = 3.6 μM. |
10882374 |
HFF |
Function assay |
|
|
|
Compound was tested for antiviral activity against human cytomegalovirus (HCMV) by yield reduction assay using HFF cells, IC90 = 1.6 μM. |
10882375 |
vero |
Antiviral assay |
|
|
|
In vitro antiviral and anticellular activity was evaluated against herpes simplex virus HSV-1 (F strain) in vero cells tissue culture, ID50 = 0.3 μM. |
2993615 |
vero |
Antiviral assay |
|
|
|
In vitro antiviral and anticellular activity was evaluated against herpes simplex virus HSV-2 (G strain) in vero cells., ID50 = 1.3 μM. |
2993615 |
HCMV AD 169 |
Antiviral assay |
|
|
|
In vitro antiviral and anticellular activity was evaluated against human cytomegalovirus (HCMV AD 169) in (HCMV AD 169) cells., ID50 = 6 μM. |
2993615 |
Vero |
Antiviral assay |
|
|
|
In vitro antiviral activity was measured against HSV-1(F) in Vero cells, ID50 = 0.2 μM. |
3009811 |
Vero |
Antiviral assay |
|
|
|
In vitro antiviral activity was measured against HSV-2(G) in Vero cells, ID50 = 1.6 μM. |
3009811 |
MRC5 |
Antiviral assay |
|
|
|
In vitro antiviral activity was measured against HCMV(AD-169) in MRC5 cells, ID50 = 5 μM. |
3009811 |
Vero |
Antiviral assay |
|
|
|
In vitro antiviral activity was measured against HSV-1 (F delta 305) in Vero cells, ID50 = 10 μM. |
3009811 |
Vero |
Antiviral assay |
|
|
|
Antiviral activity determined against herpes simplex type 1 (F strain) by plaque reduction in Vero cells, ID50 = 0.2 μM. |
3016263 |
vero |
Antiviral assay |
|
|
|
Antiviral activity was determined in plaque reduction assay in vero cells against HSV-1 F strain, ID50 = 0.2 μM. |
3871860 |
E6SM |
Antiviral assay |
|
|
|
Antiviral activity against HSV1 KOS-induced cytopathogenicity in E6SM cells, MIC = 0.096 μM. |
17092728 |
E6SM |
Antiviral assay |
|
|
|
Antiviral activity against HSV2 G-induced cytopathogenicity in E6SM cells, MIC = 0.096 μM. |
17092728 |
E6SM |
Antiviral assay |
|
|
|
Antiviral activity against HSV1 TK- KOS ACV-induced cytopathogenicity in E6SM cells, MIC = 0.8 μM. |
17092728 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity, MIC = 0.0064 μM. |
17672445 |
HEL |
Antiviral assay |
|
|
|
Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity, MIC = 0.032 μM. |
17672445 |
neural precursor cells |
Function assay |
|
|
|
Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay |
17417631 |
A673 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells |
29435139 |
Saos-2 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells |
29435139 |
BT-37 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells |
29435139 |
BT-12 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells |
29435139 |
MG 63 (6-TG R) |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells |
29435139 |
OHS-50 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells |
29435139 |
Rh41 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells |
29435139 |
SJ-GBM2 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells |
29435139 |
SK-N-MC |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells |
29435139 |